摘要:
The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).
摘要:
Disclosed is a process for preparing a 3-hydroxy-7- mercaptopyrazolo[4,3-d]pyrimidine compound represented by the general formula (IX): wherein R¹ is a hydrogen atom, an alkyl group having l to 4 carbon atoms, a phenyl group or a substituted phenyl group, which comprises: from a pyrazole compound represented by the general formula (III): wherein R¹ is the same as defined above. Also disclosed are pyrazole compounds represented by the general formula (I): wherein: R¹ is a hydrogen atom, an alkyl group having l to 4 carbon atom, a phenyl group or a substituted phenyl group: X is a nitroso group, an amino group or (R²)₂NCH=N- (wherein R² is an alkyl group having l to 3 carbon atoms): and Y is -C(O)NH₂ when R¹ is an alkyl group having l to 4 carbon atoms, a phenyl group or a substituted phenyl group and X is a nitroso group, or -C(O)NH₂ when R¹ is a hydrogen atom, an alkyl group having l to 4 carbon atoms, a phenyl group or a substituted phenyl group and X is an amino group, or CN or -C(S)NH₂ when R¹ is a hydrogen atom, an alkyl group having l to 4 carbon atoms, a phenyl group or a substituted phenyl group and X is (R²)₂NCH=N- (wherein R² is the same as defined above. The compounds serve as intermediate for preparing the compound of the formula (IX).
摘要:
A silver halide color photographic light-sensitive material comprising a support having coated thereon at least one silver halide emulsion layer, the color photographic light-sensitive material having at least one layer containing at least one 2-equivalent magenta coupler of the 5-pyrazolone type represented by the following general formula (I): wherein W represents a phenyl group substituted with at least one substituent selected from the group consisting of a halogen atom, an alkyl group, an alkoxy group, an alkoxycarbonyl group and a cyano group; Y represents an acylamino group or an anilino group; and Z represents a group capable of being released upon coupling, and at least one compound represented by the following general formula (II): wherein R' and R Z , which may be the same or different, each represents a hydrogen atom, an alkyl group or an aryl group, provided that both R' and R' do not represent hydrogen atoms atthe same time; Z' represents a methine group, a substituted methine group orthe group-N=; and Q represents an atomic group which contains a nitrogen atom, a sulfur atom or an oxygen atom and is necessary to form a 5-membered ora 6-membered heterocyclic ring together with the group-C=Z 1 -. The silver halide color photographic light-sensitive material can provide an excellent magenta color image without the occurrence of stain, even when the color photographic material is processed in a processing solution under the running condition.
摘要:
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
摘要:
The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).
摘要:
A charge control agent which contains no harmful metals, has no fear of easily firing or exploding, and has an excellent charging effect; and a toner of the negative electrification type. The monoazo iron complex compound is represented by the formula [1]. In the formula, A1, A2, B1, and B2 each independently represents hydrogen, alkyl, or halogeno; J represents hydrogen, an alkali metal, NH4, or alkylammonium, and may be two or more of these; X1 and X2 each independently represents hydrogen, alkyl, or halogeno; and Y1 and Y2 each independently represents hydrogen, alkyl, or a substituted aromatic group, provided that not all of A1, A2, B1, B2, X1, X2, Y1, and Y2 are hydrogen.